Loading...

APC anti-mouse CD279 (PD-1) Antibody

Pricing & Availability
Clone
29F.1A12 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, Programmed Death-1, PDCD1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
29F.1A12 APC_033010
Con-A and IL-2 stimulated C57BL/6 splenocytes (3 days) stained with 29F.1A12 APC
  • 29F.1A12 APC_033010
    Con-A and IL-2 stimulated C57BL/6 splenocytes (3 days) stained with 29F.1A12 APC
See APC spectral data
Cat # Size Price Quantity Check Availability Save
135209 25 µg 91€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
135210 100 µg 237€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.

Application References
  1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
  2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
  3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
  4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
  5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  2. Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed
  3. Shimba A et al. 2018. Immunity. 48(2):286-298 . PubMed
  4. Wang J, et al. 2019. Front Immunol. 9:3157. PubMed
  5. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  6. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  7. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  8. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  9. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
  10. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  11. Stokes J, et al. 2020. Oncoimmunology. 9:1758011. PubMed
  12. Smith T, et al. 2014. J Immunol. 193:3409. PubMed
  13. Onishi M, et al. 2015. J Immunol. 194:2673. PubMed
  14. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  15. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  16. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  17. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  18. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  19. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  20. Mandal RK, et al. 2021. Cell Reports. 35(6):109094. PubMed
  21. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  22. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  23. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  24. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  25. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  26. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  27. Wu Q, et al. 2021. Cancer Commun (Lond). Online ahead of prin. PubMed
  28. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  29. Almshayakhchi R, et al. 2021. Front Oncol. 11:636977. PubMed
  30. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  31. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  32. Stewart JM, et al. 2020. ACS Biomater Sci Eng. 6:5941. PubMed
  33. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  34. Molina MS, et al. 2021. Front Immunol. 12:699128. PubMed
  35. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  36. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  37. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  38. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
  39. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  40. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  41. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  42. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  43. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  44. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  45. Campisi L, et al. 2022. Nature. 606:945. PubMed
  46. Chen Q, et al. 2022. Cell Rep. 39:110990. PubMed
  47. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  48. Molina MS, et al. 2022. PLoS One. 17:e0273075. PubMed
  49. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  50. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  51. Xiao J, et al. 2023. J Clin Invest. 133: . PubMed
  52. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  53. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  54. Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed
  55. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
RRID
AB_2251944 (BioLegend Cat. No. 135209)
AB_2159183 (BioLegend Cat. No. 135210)

Antigen Details

Structure
A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function
Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, T cells
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org
Go To Top Version: 2    Revision Date: 09/11/2014

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account